Background: Urinary tract infections are still a real public health concern. The aim of this study was to identify the bacteria strains involved in urinary tract infections and to determine their antibiotic resistance...Background: Urinary tract infections are still a real public health concern. The aim of this study was to identify the bacteria strains involved in urinary tract infections and to determine their antibiotic resistance profiles. Methods: Two kinds of studies were performed. The retrospective study was carried out for 2 years (from January 2018 to December 2019), and the prospective study was extended over a period of 6 months (from January to June 2020). Isolation and identification of bacteria strains were performed using conventional microbiology techniques. The strains’ resistance profiles were determined by the diffusion method on Mueller-Hinton according to the criteria of EUCAST- 2015. Fourteen (14) antibiotic discs were used depending on the isolated germ. Results: A total of 187 bacterial strains were isolated from 82 men and 105 women. Among the germs identified, 77.54% were Enterobacteriaceae and 13.36% were cocci strains. Non-fermentative gram-negative bacilli accounted for 9.08% of the isolated bacteria. The results showed that the majority of Enterobacteriaceae strains were resistant to beta-lactams: 100% to amoxicillin, 98.75% to amoxicillin + clavulanic acid, 41.76% to ceftriaxone, and 43.14% to ceftazidime. These findings were obtained with fluoroquinolones and aminoglycosides: 50.09% with ciprofloxacin, 54.04% with norfloxacin, and 22.58% with amikacin. 8.75% of the Enterobacteriaceae strains tested were resistant to imipenem. The same trends were observed with non-fer- mentative bacteria. As for the gram-positive bacteria isolated during our study, 13.33% were resistant to vancomycin, 21.05% to gentamicin, 94.12% to penicillin G, 88.89% to ampicillin, 77.78% to cefotaxime, 63.63% to kanamycin, and 52.63% to erythromycin. Conclusion: This study revealed, as in other studies, that Enterobacteriaceae strains remain the most incriminated bacteria strains in urinary tract infections, with a strong resistance to antibiotics. It is important that actions be taken to reduce the incidence of urinary tract infections and mitigate the spread of resistant bacteria.展开更多
Knowledge of the clinical and biological profile of patients infected with HIV and hepatitis B and/or C is essential in order to identify and implement effective management strategies. Methods: This was a retrospectiv...Knowledge of the clinical and biological profile of patients infected with HIV and hepatitis B and/or C is essential in order to identify and implement effective management strategies. Methods: This was a retrospective descriptive study from January 01, 2016 to June 01, 2021. Adult patients aged at least 18 years infected with HIV type 1 and/or 2, na?ve to ARV treatment. Univariate analyses were assessed using Pearson’s Chi2 test. The Student Newman test was used for comparison between groups using R software version 4.0.2. Objective: To draw up the epidemiological, clinical, paraclinical and evolutionary profiles of HIV-treated-patients in relation to HIV/HBV and HIV/HCV co-infections in order to allow the identification and the implementation of effective management strategies. Results: Of the 379 patients included 280 (73.88%) were women. At treatment initiation, the mean age was 40.14 ± 11.84 years. The majority of patients consulted at WHO stage III (51.45%). Clinical suspicion was the most frequent screening circumstance (51.71%). The pathologies frequently reported at the first consultation were diarrhea (28%) and shingles (16%). Body mass index was normal in 50.5% of patients. HIV1 infection was the majority (91.03%). A total of 270 had a CD4 count at treatment initiation. The mean CD4 cell count was 304.17 ± 242.06 cells/μL, and 116 (42.59%) of them had a CD4 ≤ 200 cells/μL. Viral load at treatment initiation was documented in 62 patients (16.35%) and 70.97% of them had a detectable viral load (greater than 1000 copies/mL). The clinical and biological evolution was relatively good in patients after therapeutic initiation. HIV-HBV co-infection was 24.11% and HIV-HCV co-infection was 2.26%. The mortality rate was 3.69%. Conclusion: These results reflect a significant delay in HIV infection diagnosis. Furthermore, hepatitis B and/or C is co-infections that increasingly affect people living with HIV. It also appears that COVID 19 disease has had a strong impact on patient management. Thus, new screening strategies must be implemented to encourage early diagnosis of HIV, hepatitis B and C. Effective strategies are also necessary to fight HIV in the context of epidemics and/or pandemics.展开更多
文摘Background: Urinary tract infections are still a real public health concern. The aim of this study was to identify the bacteria strains involved in urinary tract infections and to determine their antibiotic resistance profiles. Methods: Two kinds of studies were performed. The retrospective study was carried out for 2 years (from January 2018 to December 2019), and the prospective study was extended over a period of 6 months (from January to June 2020). Isolation and identification of bacteria strains were performed using conventional microbiology techniques. The strains’ resistance profiles were determined by the diffusion method on Mueller-Hinton according to the criteria of EUCAST- 2015. Fourteen (14) antibiotic discs were used depending on the isolated germ. Results: A total of 187 bacterial strains were isolated from 82 men and 105 women. Among the germs identified, 77.54% were Enterobacteriaceae and 13.36% were cocci strains. Non-fermentative gram-negative bacilli accounted for 9.08% of the isolated bacteria. The results showed that the majority of Enterobacteriaceae strains were resistant to beta-lactams: 100% to amoxicillin, 98.75% to amoxicillin + clavulanic acid, 41.76% to ceftriaxone, and 43.14% to ceftazidime. These findings were obtained with fluoroquinolones and aminoglycosides: 50.09% with ciprofloxacin, 54.04% with norfloxacin, and 22.58% with amikacin. 8.75% of the Enterobacteriaceae strains tested were resistant to imipenem. The same trends were observed with non-fer- mentative bacteria. As for the gram-positive bacteria isolated during our study, 13.33% were resistant to vancomycin, 21.05% to gentamicin, 94.12% to penicillin G, 88.89% to ampicillin, 77.78% to cefotaxime, 63.63% to kanamycin, and 52.63% to erythromycin. Conclusion: This study revealed, as in other studies, that Enterobacteriaceae strains remain the most incriminated bacteria strains in urinary tract infections, with a strong resistance to antibiotics. It is important that actions be taken to reduce the incidence of urinary tract infections and mitigate the spread of resistant bacteria.
文摘Knowledge of the clinical and biological profile of patients infected with HIV and hepatitis B and/or C is essential in order to identify and implement effective management strategies. Methods: This was a retrospective descriptive study from January 01, 2016 to June 01, 2021. Adult patients aged at least 18 years infected with HIV type 1 and/or 2, na?ve to ARV treatment. Univariate analyses were assessed using Pearson’s Chi2 test. The Student Newman test was used for comparison between groups using R software version 4.0.2. Objective: To draw up the epidemiological, clinical, paraclinical and evolutionary profiles of HIV-treated-patients in relation to HIV/HBV and HIV/HCV co-infections in order to allow the identification and the implementation of effective management strategies. Results: Of the 379 patients included 280 (73.88%) were women. At treatment initiation, the mean age was 40.14 ± 11.84 years. The majority of patients consulted at WHO stage III (51.45%). Clinical suspicion was the most frequent screening circumstance (51.71%). The pathologies frequently reported at the first consultation were diarrhea (28%) and shingles (16%). Body mass index was normal in 50.5% of patients. HIV1 infection was the majority (91.03%). A total of 270 had a CD4 count at treatment initiation. The mean CD4 cell count was 304.17 ± 242.06 cells/μL, and 116 (42.59%) of them had a CD4 ≤ 200 cells/μL. Viral load at treatment initiation was documented in 62 patients (16.35%) and 70.97% of them had a detectable viral load (greater than 1000 copies/mL). The clinical and biological evolution was relatively good in patients after therapeutic initiation. HIV-HBV co-infection was 24.11% and HIV-HCV co-infection was 2.26%. The mortality rate was 3.69%. Conclusion: These results reflect a significant delay in HIV infection diagnosis. Furthermore, hepatitis B and/or C is co-infections that increasingly affect people living with HIV. It also appears that COVID 19 disease has had a strong impact on patient management. Thus, new screening strategies must be implemented to encourage early diagnosis of HIV, hepatitis B and C. Effective strategies are also necessary to fight HIV in the context of epidemics and/or pandemics.